Acid alpha-glucosidase and fragments thereof
View Patent ↗Targeted acid alpha-glucosidase therapeutics that localize to the lysosome are provided. The targeted therapeutics include a therapeutic agent, GAA, and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.
1. A targeted therapeutic fusion protein comprising amino acid residues 70-952 of human acid alpha-glucosidase (GAA) (SEQ ID NO:54) and a peptide tag comprising residue 1 followed by residues 8-67 of wild-type mature human insulin-like growth factor II (IGF-II) (SEQ ID NO:70), residues 2-7 of mature human IGF-II (SEQ ID NO:70) being deleted, wherein the peptide tag is linked to amino acid residue 70 of human GAA (SEQ ID NO:54).
2. The targeted therapeutic fusion protein of claim 1 , further comprising a spacer between the amino acid residues 70-952 of human GAA and the peptide tag.
3. The targeted therapeutic fusion protein of claim 2 , wherein the spacer is a Gly-Ala-Pro (SEQ ID NO:69) linker.